Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical cancer in Chinese women: a case-control analysis.

[1]  Hongbing Shen,et al.  Interactions of IL-12A and IL-12B Polymorphisms on the Risk of Cervical Cancer in Chinese Women , 2009, Clinical Cancer Research.

[2]  D. Pinto,et al.  The p53 R72P polymorphism does not influence cervical cancer development in a portuguese population: A study in exfoliated cervical cells , 2008, Journal of medical virology.

[3]  D. Pinto,et al.  Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. , 2007, International journal of molecular medicine.

[4]  E. Yim,et al.  Novel interaction between HPV E6 and BARD1 (BRCA1-associated ring domain 1) and its biologic roles. , 2007, DNA and cell biology.

[5]  Hongbing Shen,et al.  Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis , 2007, Breast Cancer Research and Treatment.

[6]  H. Lawson,et al.  Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2007, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[7]  R. Roden,et al.  How will HPV vaccines affect cervical cancer? , 2006, Nature Reviews Cancer.

[8]  M. Ciotti,et al.  The p53 codon 72 arg/arg homozygous women in central Italy are at increased risk for HPV infections. , 2006, Anticancer research.

[9]  J. Doorbar,et al.  Molecular biology of human papillomavirus infection and cervical cancer. , 2006, Clinical science.

[10]  E. Rosen,et al.  BRCA1 Interaction with Human Papillomavirus Oncoproteins* , 2005, Journal of Biological Chemistry.

[11]  A. Hengstermann,et al.  Growth Suppression Induced by Downregulation of E6-AP Expression in Human Papillomavirus-Positive Cancer Cell Lines Depends on p53 , 2005, Journal of Virology.

[12]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[13]  M. Grace,et al.  Mechanisms of Human Papillomavirus-Induced Oncogenesis , 2004, Journal of Virology.

[14]  K. Iwabuchi,et al.  Loss of heterozygosity analysis in uterine cervical adenocarcinoma. , 2004, Gynecologic oncology.

[15]  Katia Basso,et al.  Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. , 2004, Cancer research.

[16]  H. Campbell,et al.  Accuracy of reporting of family history of colorectal cancer , 2004, Gut.

[17]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[18]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[19]  Shu Ye,et al.  PIRA PCR designer for restriction analysis of single nucleotide polymorphisms , 2001, Bioinform..

[20]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[21]  N. Shao,et al.  The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter , 1999, Oncogene.

[22]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[23]  Hui Tian,et al.  BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.

[24]  T. Ouchi,et al.  BRCA1 regulates p53-dependent gene expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Clayton,et al.  Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. , 1997, Human molecular genetics.

[26]  M. Skolnick,et al.  Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. , 1996, Human molecular genetics.

[27]  A. Zuckerman,et al.  IARC Monographs on the Evaluation of Carcinogenic Risks to Humans , 1995, IARC monographs on the evaluation of carcinogenic risks to humans.

[28]  N. Boyd,et al.  Accuracy of family cancer history in breast cancer patients , 1994, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[29]  K. Münger,et al.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.

[30]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[31]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[32]  L. Strong,et al.  Accuracy of family history of cancer obtained through interviews with relatives of patients with childhood sarcoma. , 1994, Journal of clinical epidemiology.